JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in the coming year. After an explosive opening marked by a suite of ...

In separate presentations, the CEOs of Bristol Myers Squibb, Pfizer and Merck laid out their plans to overcome high-profile losses of exclusivity (LOEs) slated to dent sales through the end of the ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of the year, accelerating the company’s efforts to protect its top ...

Executives at Amgen made the case for MariTide’s differentiation, while Merck’s CEO contended that Keytruda’s coming loss of exclusivity can be managed. SAN FRANCISCO — For any hopes the dealmaking ...

Summit Therapeutics (NASDAQ:SMMT), a drug developer challenging pharma giant Merck's (NYSE:MRK) dominance in lung cancer, won a new buy recommendation from Truist on Wednesday based on its deal ...

The Chinese contract drugmaker will sell its vaccine factory in Dundalk, Ireland, to U.S.-based Merck for about $500 million, it said in an exchange filing late Monday. The facility, with a net ...

Jan 6 (Reuters) - China's WuXi Biologics (2269.HK), opens new tab said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co (MRK.N), opens new tab for about $500 ...

The acquisition from Wuxi Biologics, the embattled CDMO named in the BIOSECURE Act, marks another expansion of Merck’s manufacturing operations in Ireland. Facing increasing global pressure, WuXi ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of data from the Phase 2 waveLINE-007 trial ...

Also, one downstream optimization showcase for UF/DF/SPTFF will be highlighted. The talk will wrap up by presenting a future vision and emphasizing the necessity for these modeling approaches to ...